Background Available data show that COVID-19 vaccines may be less effective in
immunocompromised populations, who are at increased risk of severe COVID-19 …

Abstract The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management
of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity …

Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus
disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided …

Background By depleting circulating B lymphocytes, rituximab time-dependently suppresses
coronavirus disease 2019 (COVID-19) vaccines' humoral immunogenicity for a prolonged …

Treatment with rituximab (RTX) blunts SARS-CoV-2 vaccination-induced humoral response.
We sought to identify predictors of a positive immunogenic response to the BNT162b2 …

Many patients with systemic autoimmune rheumatic diseases (SARDs) require
immunosuppression to reduce disease activity, but this also has important possible …

Rituximab (RTX), an important therapeutic option for patients with rheumatic diseases, has
been shown to reduce immune responses to various vaccines. We asked whether following …

Most trials on mRNA vaccines against SARS-CoV-2 did not include patients with chronic
kidney disease (CKD), hemodialysis (HD) patients, or kidney transplant recipients (KTR) …

To the editor: The case fatality ratio of coronavirus disease 2019 (COVID-19) in kidney
transplant recipients is between 10% and 30%, 1, 2 underscoring the importance of …

With the roll-out of coronavirus disease 2019 (COVID-19) vaccines, it has become clear that
vaccinating the majority of the population worldwide will be the most important element to …